Mark Udell - 01 Jan 2018 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)

Reporting relationship: Chief Accounting Officer
Issuer ticker: AVRW
Reported as of: 01 Jan 2018
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 May 2021, 19:40:19 UTC
Source filing: View source filing
Reporting owner signature: /s/ Mark Udell

Key filing fact

Mark Udell filed Form 4 for Cure Pharmaceutical Holding Corp. (AVRW) on 27 May 2021.

Key facts

This page summarizes Mark Udell's Form 4 filing for Cure Pharmaceutical Holding Corp. (AVRW).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 May 2021, 19:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVRW transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 01 Jan 2018
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.7400
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option becomes exercisable on the basis determined by the equity incentive plan with 6.25% of the option vesting on the first quarter anniversary of vesting start date. For each additional quarter of the participant's service the option will continue to vest until the vested ratio is 100%. This late filing is due to an inadvertent administrative error and not any error of the reporting person.